Tuesday, June 16, 2009
Revenge of the gram-negatives!
A new report for the pharmaceutical industry states that the market for drugs to treat hospital-acquired gram-negative organisms will increase by $1 billion over the next 10 years. The report notes that the market for gram-positive drugs has been more lucrative, but now the opportunities for gram-positive drugs are declining. Let's hope that Pharma is successful in its quest for new gram-negative drugs given the worsening problems we are encountering with highly resistant gram-negative infections and few agents available currently for their treatment.
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati... -
This is a guest post by Jorge Salinas, MD, Hospital Epidemiologist at the University of Iowa Hospitals & Clinics. There is virtually no...
-
I’m surprised that we can’t stop arguing about the modes of SARS-CoV-2 transmission, despite the fact that most experts (including our frie...
No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.